Eli Lilly and Company (India) Pvt. Ltd. has launched Mounjaro KwikPen (tirzepatide) across India. Approved by the Central Drugs Standard Control Organisation (CDSCO), this once-weekly, prescription-only treatment offers adults living with type 2 diabetes and obesity a convenient and personalized way to manage their health.
Mounjaro is the first medicine to work on two natural hormones in the body, GIP and GLP-1, which help regulate insulin and appetite. It is intended for adults with type 2 diabetes and for chronic weight management in people with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) who have at least one weight-related health issue.
Doses, costs, and how it works
The prefilled KwikPen is multi-dose and for single-patient use. Each pen contains four doses and comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. This allows doctors to tailor treatment to a patient’s specific needs. Prices range from Rs 14,000 per month for the 2.5 mg pen to Rs 27,500 per month for the 12.5 mg and 15 mg pens.
Winselow Tucker, President and General Manager of Lilly India, said, “The launch of Mounjaro KwikPen is a step forward in caring for type 2 diabetes and obesity. This pen makes treatment easier and helps doctors create personalized plans for better patient outcomes.”
How Mounjaro works?
Mounjaro is a single medicine that activates GIP and GLP-1 hormones, both of which are naturally produced in the body. These hormones help control blood sugar by improving insulin secretion and reducing glucagon levels, while also improving insulin sensitivity. Mounjaro also slows down digestion slightly, helping the body absorb nutrients more steadily.
Mounjaro affects areas of the brain that regulate hunger, helping patients reduce body weight and fat mass while controlling appetite. Studies have shown that it can significantly improve blood sugar levels and support weight loss in adults living with type 2 diabetes and obesity.
Points to keep in mind before trying
Mounjaro is strictly prescription-only and should be used under a doctor’s guidance. It is not approved for cosmetic weight loss, and patients should consult a doctor first to know if it is suitable for them.
The availability of Mounjaro KwikPen across India provides a simple, once-weekly option for managing type 2 diabetes and obesity. With the number of adults living with these conditions rising in the country, experts say Mounjaro could play an important role in helping patients improve their overall health and quality of life.
Mounjaro offers an approach that not only helps control blood sugar and body weight but also supports long-term care in a way that fits into patients’ daily routines. Doctors can now provide more personalized treatment plans, while patients benefit from a simpler, manageable, and effective therapy for two serious health conditions.
